Factores asociados a falla terapéutica de medicamentos biológicos tipo Anti-TNF en pacientes con artritis reumatoide en la IPS Biomab
Ferrer Acosta, Pamela Alejandra
Higuera Rodríguez, Astrid Katherine
Background: Rheumatoid arthritis is a chronic behavioral inflammatory disease where its most effective therapeutic intervention is based on combined pharmacological therapies and different clinical specialties, as studies indicate that there are different sociodemographic, clinical and pharmacological reasons that influence the result of the therapy. Objective: The objective of this study was to evaluate the factors associated with presenting therapeutic failure in anti-TNF biological drugs during the treatment for rheumatoid arthritis from January 2017 to December 2019 at the IPS BIOMAB in the city of Bogotá. Methods: The study was observational, analytical of cases and controls. We worked with 139 cases and 139 controls that met the inclusion criteria for the study. Results: Of the total sample, 83.3% corresponded to the female gender, the average age was 58 years, the probability of therapeutic failure was 30%, and Certolizumab has a higher probability of failure (p 0.047), as risk is identified being a Young adult (OR 1.650), having comorbidities such as DM (OR 4.769), CVD (OR 2.069) and having adherence to pharmacological treatment (OR 0.193), there was no difference with gender, comorbidities not mentioned and being adherent to the model of the IPS. Conclusions: It is concluded that the occupation: active subcategory decreases the probability that the patient in a period of 3 years will present a therapeutic failure associated with a treatment with biologics twice compared to the group of those who are unemployed, with a statistically significant difference between groups (p 0.001). Additionally, the risk factors that can predict a therapeutic failure are the prescribed medications, having comorbidities, the number of previous ARMDs and adherence to pharmacological treatment.